Litcius/Paper detail

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes

Manoj Kumar Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo

2022Reviews in Endocrine and Metabolic Disorders144 citationsDOIOpen Access PDF

Topics & Concepts

SemaglutideMedicineType 2 diabetesGlucagon-like peptide 1 receptorAdverse effectDiabetes mellitusAgonistPopulationInternal medicinePharmacologyHypoglycemiaDrugPharmacotherapyEndocrinologyPharmacistDulaglutideGlucagon-like peptide-1Weight lossGlucagonClinical trialGlucagon receptorExenatideDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsBariatric Surgery and Outcomes
Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes | Litcius